The balance sheet of benefits and harms of breast cancer population-based screening in Europe: Outcome research, practice and future challenges

Women's Health

Volumn 11, Issue 6, 2015, Pages 883-890

  Broeders, Mireille ^a,b   Paci, Eugenio ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Dutch Ref Ctr Breast Cancer Screen   (Netherlands)

^c Cancer Prevention and Research Institute   (Italy)

Author keywords

breast cancer; breast cancer mortality; outcome research; overdiagnosis; population based screening; screening benefits; screening harms; screening mammography

Indexed keywords

BREAST CANCER; BREAST DENSITY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; COMMUNICATION SKILL; EUROPE; FALSE POSITIVE RESULT; HIGH RISK POPULATION; HUMAN; MAMMOGRAPHY; MASS SCREENING; OVERDIAGNOSIS; PATIENT DECISION MAKING; PERSONALIZED MEDICINE; REVIEW; ADVERSE EFFECTS; BREAST NEOPLASMS; EARLY CANCER DIAGNOSIS; FEMALE; MIDDLE AGED; PROCEDURES; RISK ASSESSMENT;

BREAST NEOPLASMS; EARLY DETECTION OF CANCER; EUROPE; FEMALE; HUMANS; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; RISK ASSESSMENT;

EID: 84951927327     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.15.34     Document Type: Review

References (36)

1. Olsen O, Gøtzsche PC. Screening for breast cancer with mammography. Cochrane Database Syst. Rev. 4, CD001877 (2001).
2. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 380, 1778-1786 (2012).
3. Biller-Andorno N, Jüni P. Abolishing mammography screening programs? A view from the Swiss Medical Board. N. Engl. J. Med. 370(21), 1965-1967 (2014).
4. Wald N, Frost C, Cuckle H. Breast cancer screening: The current position. BMJ 302(6780), 845-846 (1991).
5. Forrest Report, National Health Service, UK. www.cancerscreening.nhs.uk/breastscreen/publications
6. Broeders MJ, Scharpantgen A, Ascunce N et al. Comparison of early performance indicators for screening projects within the European Breast Cancer Network: 1989-2000. European Breast Cancer Network. Eur. J. Cancer Prev. 14(2), 107-101 (2005).
7. European Guidelines For Quality Assurance In Breast Cancer Screening And Diagnosis (4th Edition). Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (Eds). Office for Official Publications of the European Communities, Luxembourg (2006).
8. von Karsa L, Anttila A, Ronco G et al. Cancer screening in the European Union. In:Report on the Implementation of the Council Recommendation on Cancer Screening-First Report. European Commission, Luxembourg (2008).
9. Giordano L, von Karsa L, Tomatis M et al. Mammographic screening programmes in Europe: organization, coverage and participation. J. Med. Screen. 19(Suppl. 1), 72-82 (2012).
10. Hofvind S, Ponti A, Patnick J et al. False positive results in mammographic screening for breast cancer in Europe: A literature review and survey of service screening programmes. J. Med. Screen. 19(Suppl. 1), 57-66 (2012).
11. Paci E; EUROSCREEN Working Group. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. J. Med. Screen. 19(Suppl. 1), 5-13 (2012).
12. Moss SM, Nyström L, Jonsson H et al. The impact of mammographic screening on breast cancer mortality in Europe: A review of trend studies. J. Med. Screen. 19(Suppl. 1), 26-32 (2012).
13. Autier P, Boniol M, Gavin A, Vatten LJ. Breast cancer mortality in neighboring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 343, d4411 (2011).
14. Njor S, Nyström L, Moss S et al. Breast cancer mortality in mammographic screening in Europe: A review of incidencebased mortality studies. J. Med. Screen. 19(Suppl. 1), 33-41 (2012).
15. Broeders M, Moss S, Nyström L et al. The impact of mammographic screening on breast cancer mortality in Europe: A review of observational studies. J. Med. Screen. 19(Suppl. 1), 14-25 (2012).
16. Verbeek AL, Broeders MJ. Evaluation of cancer service screening: case referent studies recommended. Stat. Methods Med. Res. 19(5), 487-505 (2010).
17. Demissie K, Mills OF, Rhoads GG. Empirical comparison of the results of randomized controlled trials and casecontrol studies in evaluating the effectiveness of screening mammography. J. Clin. Epidemiol. 51(2), 81-91 (1998).
18. Paap E, Verbeek A, Puliti D, Broeders M, Paci E. Minor influence of self-selection bias on the effectiveness of breast cancer screening in case-control studies in The Netherlands. J. Med. Screen. 18(3), 142-146 (2011).
19. Paci E, Duffy S. Overdiagnosis and overtreatment of breast cancer: overdiagnosis and overtreatment in service screening. Breast Cancer Res. 7(6), 266-270 (2005).
20. Puliti D, Miccinesi G, Paci E. Overdiagnosis in breast cancer: design and methods of estimation in observational studies. Prev. Med. 53(3), 131-133 (2011).
21. International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention. Breast Cancer Screening (Vol 7). Harri Vainio H, Bianchini F (Eds). IARC Press, Lyon, France (2002).
22. Puliti D, Duffy SW, Miccinesi G et al. Overdiagnosis in mammographic screening for breast cancer in Europe: A literature review. J. Med. Screen. 19(Suppl. 1), 42-56 (2012).
23. de Gelder R, Heijnsdijk EA, van Ravesteyn NT, Fracheboud J, Draisma G, de Koning HJ. Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol. Rev. 33(1), 111-121 (2011).
24. Moss S. Overdiagnosis and overtreatment of breast cancer: overdiagnosis in randomized controlled trials of breast cancer screening. Breast Cancer Res. 7(5), 230-234 (2005).
25. Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP. Rate of overdiagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study. BMJ 332(7543), 689-692 (2006).
26. Miller AB, Wall C, Baines C J, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomized screening trial. BMJ 348, g366 (2014).
27. Duffy SW, Parmar D. Overdiagnosis in breast cancer screening: The importance of length of observation period and lead time. Breast Cancer Res. 15, R41 (2013).
28. Wang AT, Vachon CM, Brandt KR, Ghosh K. Breast density and breast cancer risk: A practical review. Mayo Clin. Proc. 89(4), 548-557 (2014).
29. Domingo L, Salas D, Zubizarreta R et al. Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain. Breast Cancer Res. 16(1), R3 (2014).
30. Darabi H, Czene K, Zhao W, Liu J, Hall P, Humphreys K. Breast cancer risk prediction and individualized screening based on common genetic variation and breast density measurement. Breast Cancer Res. 14(1), R25 (2012).
31. Vilaprinyo E, Forné C, Carles M et al. Cost-effectiveness and harm-benefit analyses of risk-based screening strategies for breast cancer. PLoS ONE 9(2), e86858 (2014).
32. Meisel SF, Pashayan N, Rahman B et al. Adjusting the frequency of mammography screening on the basis of genetic risk: attitudes among women in the UK. Breast 24(3), 237-241 (2015).
33. Sestak I, Cuzick J. Update on breast cancer risk prediction and prevention. Curr. Opin. Obstet. Gynecol. 27(1), 92-97 (2015).
34. Paci E, Giorgi Rossi P. Tailored screening for breast cancer in premenopausal women: not just looking at sensitivity, but aiming to reduce burden. Womens Health (Lond. Engl.) 6(4), 477-479 (2010).
35. O'Donoghue C, Esserman L. Recognizing the benefits and harms of breast cancer screening: an opportunity to target improvement. Br. J. Cancer 108(11), 2200-2201 (2013).
36. van Agt HM, Korfage IJ, Essink-Bot ML. Interventions to enhance informed choices among invitees of screening programmes-A systematic review. Eur. J. Public Health 24(5), 789-801 (2014).